Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MVA-HBVac—A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination

23 Jul 2025

Abstract excerpt

regimen employing the novel, pan-genotypic MVA-HBVac vector could overcome HBV-specific immune tolerance and lead to the initiation of clinical trials evaluating the therapeutic vaccine.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Hepatitis C virus research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40799509
DOI: 10.1016/j.omtn.2025.102641

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MVA-HBVac—A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccinationPMID 40799509Read ↗

A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice.Semantic proximity Read ↗

Hepatitis B vaccine: prophylactic, therapeutic, and diagnostic dilemma.Semantic proximity Read ↗

Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus-Specific CD8 T-Cell Responses and High Anti-Hepatitis B Surface Antigen Titers.Semantic proximity Read ↗

Adenoviruses vectored hepatitis C virus vaccine cocktails induce broadly specific immune responses against multi-genotypic HCV in mice.Semantic proximity Read ↗

DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques.Semantic proximity Read ↗

The development of a pan-genotypic T cell vaccine against hepatitis C virus using heterologous prime-boost strategies.Semantic proximity Read ↗

Type I Interferon Signaling Prevents Hepatitis B Virus-Specific T Cell Responses by Reducing Antigen Expression.Semantic proximity Read ↗

Prospects for prophylactic and therapeutic vaccines against hepatitis C virus.Semantic proximity Read ↗

Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB on nucleos (t)ide analoguesSemantic proximity Read ↗

The global impact of vaccination against hepatitis B: a historical overview.Semantic proximity Read ↗

Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccineSemantic proximity Read ↗

Humanized mouse model reveals the immunogenicity of Hepatitis B Virus vaccine candidates produced in CRISPR/Cas9-edited Nicotiana benthamianaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.